Alnylam (ALNY) Shares Fall 15% Amid Medicare Advantage Concerns and 340B Reimbursement Changes
Alnylam (ALNY) Shares Fall 15% Amid Medicare Advantage Concerns and 340B Reimbursement Changes GuruFocus
Covered in this story
Call it yourself
No calls on $ALNY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Alnylam Pharmaceuticals →Dalsna Finance is currently tracking 50 stories mentioning Alnylam Pharmaceuticals, the earliest published 8 May 2026.
Summary aggregated from GuruFocus's public RSS feed. The full reporting belongs to GuruFocus — please read it on their site.